Xencor selects proposed Phase 3 dose after positive XmAb819 kidney cancer data
Xencor reported updated Phase 1 results for XmAb819 at the ESMO Congress on October 25, 2026. At the selected 400 mcg/kg intravenous dose, 5 of 11 evaluable patients had confirmed partial responses, producing a 45.5% confirmed objective response rate, while estimated six-month progression-free survival was 82%. Xencor plans to discuss a possible accelerated-approval route with the FDA in the first half of 2027 and develop a global randomized study against tivozanib for previously treated advanced clear cell renal cell carcinoma.
Why it matters
The 400 mcg/kg selection moves XmAb819 toward registration-enabling development, although the efficacy signal comes from a small Phase 1 cohort and still requires regulatory discussions and larger trials. The proposed trial and FDA meeting create future development milestones for Xencor, but neither guarantees approval.
Key facts
- 1Xencor chose 400 mcg/kg intravenously as the proposed recommended Phase 3 dose for XmAb819. stocktitan.net
- 2The 400 mcg/kg cohort had a 45.5% confirmed objective response rate among 11 evaluable patients, with estimated six-month progression-free survival of 82%. ibtimes.com.au
- 3Xencor plans a first-half 2027 meeting with the U.S. Food and Drug Administration to discuss potential accelerated approval in selected advanced kidney-cancer populations. finance.yahoo.com
- 4The planned randomized study will test XmAb819 alone against tivozanib in patients whose disease progressed after earlier immune-checkpoint and VEGFR-targeted treatment. finance.yahoo.com
- 5Xencor expects to begin a registration-enabling study in 2027 and says its cash runway extends into 2029. rttnews.com
Open questions
- The response rate is based on only 11 evaluable patients, so durability and results in larger randomized studies remain unknown.
- The potential accelerated-approval route, trial timing and eventual regulatory outcome remain subject to FDA discussions and future data.
Summary written by AlphAI AI Desk from 14 of 14 sources. Not investment advice. Figures are as stated by the linked sources.